6.2.3.1.2. dose escalation. local control critical issue outcome rt pca. shown local failure due insufficient total dose prognostic death pca second wave metastases seen five ten years later . several rcts shown dose escalation (range 74–80 gy) significant impact 10-year biochemical relapse well metastases disease-specific mortality [644-651]. trials generally included patients several risk groups, use neoadjuvant/adjuvant ht varied (see table 6.1.6). best evidence os benefit patients intermediate- high-risk pca, low-risk pca, derives non-randomised well conducted propensity-matched retrospective analysis u.s. national cancer database kalbasi et al., including total 42,481 patients . imrt/vmat igrt used dose escalation, rates severe late side effects (> grade 3) rectum 2–4% gu tract 2–6% . concept focal boost dominant intraprostatic lesion (dil) visible mri rather global prostate dose escalation successfully validated rct 571 intermediate- high-risk patients . patients randomised 77 gy 35 fractions 2.2 gy dose plus focal boost 18 gy. additional adt given 65% patients arms. however, duration adt reported. median follow-up 72 months moderate improvement biochemical pfs (bpfs) (primary endpoint). addition, focal boosting decreased local failure (hr: 0.33) increased rate regional + distant mfs (hr: 0.58) . significant difference late gu- gi toxicity grade ≥ 2 (23% 12% vs. 28% 13%) documented. grade ≥ 3 gu-toxicity numbers 3.5% 5.6% (p > 0.05). however, longer follow-up needed assess late gu-toxicity . note, clear decrease biochemical failure increasing boost dose, individually given 18 gy. systematic review mri-defined dil focal boost studies using standard fractionation shows good tolerability improved bpfs . role using hypofractionation ultra-hypofractionation investigation. table 6.2.6: randomised trials dose escalation localised pca trialnpca conditionradiotherapy dosefollow-up (median)outcomeresultsmd andersonstudy 2011 301t1-t3, n0, m0,psa ≤ 10 ng/mlpsa 10-20 ng/mlpsa > 20 ng/ml70 vs.78 gy15 yr.dm, dsm, fffall patients:18.9% fff 70 gy12% fff 78 gy(p = 0.042)3.4% dm 70 gy1.1% dm 78 gy(p = 0.018)6.2% dsm 70 gy3.2% dsm 78 gy(p = 0.043)no difference os(p > 0.05)prog95-092010 393t1b-t2bpsa ≤ 15 ng/ml75% low-risk pts.low-risk: t1-2a,psa < 10 mg/ml,gs ≤ 6interm-risk:psa 10-15 ng/ml orgs 7 t2bhigh-risk: gs8-1070.2 vs.79.2 gy including proton boost19.8 vs. 28.8 gy8.9 yr.10-yr.astro bcfall patients:32% bf 70.2 gy17% bf 79.2 gy(p < 0.0001)low-risk patients:28% bf 70.2 gy7% bf 79.2 gy(p < 0.0001mrc rt01 2014 843t1b-t3a, n0, m0psa < 50 ng/ml neoadjuvant ht64 vs. 74 gy10 yr.bfs, os43% bfs 64 gy55% bfs 74 gy(p = 0.0003) 71%os groups (p = 0.96)dutch rando-mised phase iii trial 2014 664t1b-t4 143 pts. (neo) adjuvant ht68 vs. 78 gy110 mo.freedombiochemical(phoenix)and/or clinicalfailure at10 yr.43% fff 68 gy49% fff 78 gy(p = 0.045)getug 062011 306t1b-t3a, n0, m0psa < 50 ng/ml70 vs. 80 gy61 mo.bcf (astro)39% bf 70 gy28% bf 80 gyrtog 01262018 1,532t1b-t2bisup gradegroup 1+ psa 10-20ng/ml isup grade group 2/3 + psa < 15 ng/ml70.2 vs. 79.2 gy100 mo.os, dm, bcf (astro)75% os 70.2 gy76% os 79.2 gy6% dm 70.2 gy4% dm 79.2 gy(p = 0.05)47% bcf 70.2 gy31% bcf 79.2 gy(p < 0.001;phoenix, p < 0.001)flame trial 571eau risk classification:intermediate risk (15%)high risk (84%)77 gy (35 fx.2.2 gy) vs. 77 gy(35 fx.)+ focal boost(up 18 gy)adt (65% arms – duration unknown)72 mo. (median)bfs (5 yr.) dsm (5 yr.)bfs:92% 77 gy + boost85% 77 gy(p < 0.001, hr: 0.45)dsm: p= 0.49focal boost favour of:local control (hr: 0.33)distant mfs (hr: 0.58) adt = androgen-deprivation therapy; bf = biochemical failure; bfs = biochemical progression-free survival;dm = distant metastases; dsm = 50disease specific mortality; fff = freedom biochemical clinical failure;fx = fractions; gs = gleason score; ht = hormone therapy; isup = international society urological pathology; mfs = metastasis-free survival; mo. = months; n = number patients; os = overall survival;psa = prostate-specific antigen; yr. = year.